Evidence map›Paper›PMID 30536678›Full record

ArticleEuropean journal of heart failure2019

Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.

Pooja Dewan, Pardeep S Jhund, Li Shen, Mark C Petrie, William T Abraham, M Atif Ali, Chen-Huan Chen, Akshay S Desai, Kenneth Dickstein, Jun Huang and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Pooja DewanBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Pardeep S JhundBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Li ShenBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Mark C PetrieBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
William T AbrahamDivision of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus, OH, USA.
M Atif AliNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Chen-Huan ChenDepartment of Medicine, National Yang-Ming University School of Medicine, Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
Akshay S DesaiCardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Kenneth DicksteinUniversity of Bergen, Stavanger University Hospital, Stavanger, Norway.
Jun HuangDepartment of Cardiology, First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Songsak KiatchoosakunCardiology, Medicine, Khon Kaen University, Khon Kaen, Thailand.
Kee-Sik KimDaegu Catholic University Medical Centre, Daegu, South Korea.
Lars KøberRigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Wen-Ter LaiDivision of Cardiology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Yuhua LiaoInstitute of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ulrik M MogensenBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Byung-Hee OhSeoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Milton PackerBaylor Heart and Vascular Institute, Baylor University Medical Centre, Dallas, TX, USA.
Jean L RouleauInstitut de Cardiologie de Montréal, Université de Montréal, Montréal, Canada.
Victor ShiNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Antonio S SibuloSt. Luke's Medical Centre, Quezon City, Philippines.
Scott D SolomonCardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Piyamitr SritaraFaculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Karl SwedbergDepartment of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden.
Hiroyuki TsutsuiDepartment of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Michael R ZileMedical University of South Carolina and Ralph H. Johnson Veterans Administration Medical Centre, Charleston, SC, USA.
John J V McMurrayBritish Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsNearly 60% of the world's population lives in Asia but little is known about the characteristics and outcomes of Asian patients with heart failure with reduced ejection fraction (HFrEF) compared to other areas of the world. METHODS AND

resultsWe pooled two, large, global trials, with similar design, in 13 174 patients with HFrEF (patient distribution: China 833, India 1390, Japan 209, Korea 223, Philippines 223, Taiwan 199 and Thailand 95, Western Europe 3521, Eastern Europe 4758, North America 613, and Latin America 1110). Asian patients were younger (55.0-63.9 years) than in Western Europe (67.9 years) and North America (66.6 years). Diuretics and devices were used less, and digoxin used more, in Asia. Mineralocorticoid receptor antagonist use was higher in China (66.3%), the Philippines (64.1%) and Latin America (62.8%) compared to Europe and North America (range 32.8% to 49.6%). The rate of cardiovascular death/heart failure hospitalization was higher in Asia (e.g. Taiwan 17.2, China 14.9 per 100 patient-years) than in Western Europe (10.4) and North America (12.8). However, the adjusted risk of cardiovascular death was higher in many Asian countries than in Western Europe (except Japan) and the risk of heart failure hospitalization was lower in India and in the Philippines than in Western Europe, but significantly higher in China, Japan, and Taiwan.

conclusionPatient characteristics and outcomes vary between Asia and other regions and between Asian countries. These variations may reflect several factors, including geography, climate and environment, diet and lifestyle, health care systems, genetics and socioeconomic influences.

Indexed as

Practice Patterns, Physicians'Stroke VolumeAdrenergic beta-AntagonistsAgedAge DistributionAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAsiaAsia, EasternAsia, SoutheasternAsia, WesternCardiac Resynchronization Therapy DevicesCardiotonic AgentsCardiovascular DiseasesDigoxinDisease ManagementAdrenergic beta-AntagonistsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCardiotonic AgentsDigoxinDiureticsMineralocorticoid Receptor AntagonistsAsiaHeart failure

Identifiers

PMID30536678
PMCPMC6607486

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.